- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
International Isotopes wins Imagyn deal
Nuclear medicine start-up International Isotopes has won a major contract that will help the company in its quest to become a supplier of medical radioisotopes (SCAN 9/3/97). The company has signed a deal to provide its radioactive seeds to Imagyn
Nuclear medicine start-up International Isotopes has won a major contract that will help the company in its quest to become a supplier of medical radioisotopes (SCAN 9/3/97). The company has signed a deal to provide its radioactive seeds to Imagyn Medical Technologies, which will have exclusive worldwide rights to market the seeds for brachytherapy prostate cancer treatment, according to Newport Beach, CA-based Imagyn.
International Isotopes, of Denton, TX, will develop and manufacture the radioactive seeds for distribution through Imagyn's direct sales force. Imagyn will pay International Isotopes $1 million to develop the seeds and has agreed to purchase seeds for three years. Imagyn anticipates that it will file a 510(k) application for the company's initial brachytherapy product, iodine-125, with the Food and Drug Administration by March 31.
In other Imagyn news, the company has announced that it will close its Laguna Niguel, CA, plant and move its endoscope manufacturing facility to Costa Mesa, CA. As part of its consolidation, the firm is reducing its work force by about 120 people.
New Study Examines Agreement Between Radiologists and Referring Clinicians on Follow-Up Imaging
November 18th 2024Agreement on follow-up imaging was 41 percent more likely with recommendations by thoracic radiologists and 36 percent less likely on recommendations for follow-up nuclear imaging, according to new research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
